BriaCell Therapeutics Corp. (V:BCT*CA)

Business Focus: Bio Therapeutic Drugs

May 17, 2019 05:24 am ET
Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell Therapeutics Corp.
Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 1,698,000 common shares (the “Shares”) of BriaCell Therapeutics Corp. (BCT-TSXV) (“BriaCell”). Bondarenko acquired the Shares through the facilities of the TSX...
May 13, 2019 02:30 am ET
BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all...
Apr 23, 2019 02:30 am ET
BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that BriaCell’s clinical findings will be...
Apr 03, 2019 04:30 am ET
BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced early efficacy data of BriaCell’s novel...
Apr 02, 2019 11:15 am ET
IIROC Trading Resumption - BCT
VANCOUVER, April 2, 2019 /CNW/ - Trading resumes in:
Apr 02, 2019 10:58 am ET
BriaCell Announces Clinical Trial Collaboration Agreement with Incyte
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced a clinical trial collaboration and supply...
Apr 02, 2019 10:34 am ET
IIROC Trading Halt - BCT
VANCOUVER, April 2, 2019 /CNW/ - The following issues have been halted by IIROC:
Apr 01, 2019 02:45 pm ET
BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has upsized and closed the second and...
Mar 26, 2019 02:30 am ET
BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce it is finalizing the analysis of...
Mar 25, 2019 05:26 pm ET
Jamieson Bondarenko Acquires 5,000,000 Common Shares of BriaCell Therapeutics Corp.
Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 5,000,000 common shares (the “Shares”) of BriaCell Therapeutics Corp. (BCT-TSXV) (“BriaCell”). Bondarenko acquired the Shares through BriaCell’s...
Mar 25, 2019 12:05 pm ET
BriaCell Closes First Tranche of Previously Announced Non-Brokered Private Placement
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has closed the first...
Mar 20, 2019 12:05 pm ET
BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it intends to complete a...
Mar 18, 2019 02:30 am ET
BriaCell Welcomes BioPharma Industry Experts to its Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces changes to its Board of Directors....
Mar 07, 2019 01:30 am ET
BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire
via NetworkWire - NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview...
Feb 26, 2019 01:30 am ET
BriaCell Announces C$500,000 Equity Investment by BriaCell Director
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce a non-brokered private placement...
Feb 19, 2019 01:30 am ET
BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences
BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces it has been selected to present a poster at...
Feb 12, 2019 02:57 pm ET
Jamieson Bondarenko Acquires 11.0% Beneficial Ownership of BriaCell Therapeutics Corp.
Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 2,000,000 common shares (the “Shares”) of BriaCell Therapeutics Corp. (BCT-TSXV) (“BriaCell”). Bondarenko acquired the Shares through the facilities of the TSX...
Feb 12, 2019 01:30 am ET
BriaCell Appoints Jamieson Bondarenko to its Board of Directors
BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces the appointment of Jamieson Bondarenko to...
Jan 02, 2019 01:30 am ET
BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference
BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces the imminent clinical use of a new novel,...
Dec 06, 2018 03:30 am ET
BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announces the presentation of initial safety data in the...
Nov 20, 2018 01:54 pm ET
UPDATE - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposi
BriaCell Therapeutics Corp. (“BriaCell,” the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Bria-IMT™ will be featured in a...
Nov 19, 2018 01:30 am ET
BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
BriaCell Therapeutics Corp. (“BriaCell,” the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Bria-IMT™ will be featured in a...
Oct 09, 2018 02:30 am ET
BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®
BriaCell Therapeutics Corp. (“BriaCell”, the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that it has initiated patient dosing...
Oct 04, 2018 05:00 am ET
NetworkNewsAudio Announces Audio Press Release (APR) on BriaCell Therapeutics Corp. Leveraging Combination Studies, Immune Checkpoint Inhibitors for Potent Anti-Cancer Response
New York, New York--(Newsfile Corp. - October 4, 2018) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer Treatment," featuring BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSXV: BCT).
Oct 04, 2018 04:30 am ET
NetworkNewsAudio Announces Audio Press Release (APR) on BriaCell Therapeutics Corp. Achieving Superior Responses in Breast Cancer Immunotherapy Trials
via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer Treatment,” featuring BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT). To hear the...
Oct 03, 2018 04:30 am ET
NetworkNewsWire Announces Publication on Hope on the Horizon with Innovative Breast Cancer Therapies
via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), a client of NNW focused on developing...
Sep 26, 2018 12:13 pm ET
IIROC Trading Resumption - RTB.P; FCO; BCT; KAPA.P
VANCOUVER, Sept. 26, 2018 /CNW/ - Trading resumes in:
Sep 26, 2018 12:11 pm ET
IIROC Trade Resumption - BriaCell Therapeutics Corp.
Vancouver, British Columbia--(Newsfile Corp. - September 26, 2018) - Trading resumes in:
Sep 26, 2018 10:30 am ET
BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study
BriaCell Therapeutics Corp. (“BriaCell”, the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that it has achieved proof of concept...
Sep 26, 2018 10:08 am ET
IIROC Trade Halt - BriaCell Therapeutics Corp.
Vancouver, British Columbia--(Newsfile Corp. - September 26, 2018) - The following issues have been halted by IIROC:
Sep 26, 2018 10:04 am ET
IIROC Trading Halt - BCT
VANCOUVER, Sept. 26, 2018 /CNW/ - The following issues have been halted by IIROC:
Sep 25, 2018 02:30 am ET
BriaCell Therapeutics Corp. Discusses its Plan to Revolutionize Cancer Immunotherapy in Exclusive NetworkNewsWire Audio Interview
via NetworkWire - NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with...
Sep 21, 2018 04:30 am ET
Coverage Initiated for BriaCell Therapeutics Corp. via NetworkNewsWire
via NetworkWire – BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V) (BriaCell or the Company), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announces that it has selected...
Sep 21, 2018 02:30 am ET
BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences
Scientific findings will discuss circulating tumor cells as a biomarker of tumor response, which is key to the advancement of BriaCell's BriaDX™, a diagnostic test designed to determine which patients are most likely to respond to treatment.
Aug 28, 2018 04:00 am ET
Dr. William Williams, BriaCell’s President & CEO, is Featured in an Exclusive New Audio Interview at SmallCapVoice.com
SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President CEO, Dr....
Aug 08, 2018 02:30 am ET
BriaCell Adds New Clinical Site To Phase IIa Study in Advanced Breast Cancer and Expands R&D Team
BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that the Cancer Center of Kansas (CCK) has been added...
Jun 21, 2018 06:09 am ET
BriaCell to Hold Conference Call on Key Clinical Findings; Activities
BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to provide a Corporate Update on its activities and new...
Jun 13, 2018 08:45 am ET
BriaCell Therapeutics Corp. to Present at The MicroCap Conference on June 21st in Toronto at the Sheraton Centre Hotel
TORONTO, ON / ACCESSWIRE / June 13, 2018 / BriaCell Therapeutics Corp. ("BriaCell") (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will be presenting at this year's MicroCap Conference on June 21st in Toronto, Canada. Dr. Bill Williams, BriaCell's President and CEO will discuss Bria-IMT™, BriaCell's lead clinical candidate, its potential in treating breast cancer, and its advantages over similar immuno-oncology therapeutics. He will also discuss the clinical development plans
Jun 13, 2018 04:00 am ET
Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, Discusses Recent News and Progress in an Exclusive New Audio Interview with SmallCapVoice.com
SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT.V) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President ...
May 29, 2018 02:30 am ET
BriaCell Publishes Clinical Findings in 2018 American Society of Clinical Oncology (ASCO) Meeting
BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it will publish its clinical findings in the American...
May 21, 2018 02:30 am ET
BriaCell’s Lead Product Candidate’s Novel Mechanism of Action Published in a Reputable Immunology Journal
BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the publication of  the novel mechanism of action of...
Apr 26, 2018 02:15 pm ET
Sagittarius Capital Announces Closing of Oversubscribed IRRI-Al-Tal Private Placement and Amendment to the LOI
TORONTO, April 26, 2018 (GLOBE NEWSWIRE) -- Sagittarius Capital Corporation (NEX Board:SCX.H) ("Sagittarius" or the "Company"), a capital pool company, is pleased to announce the first closing of IRRI-Al-Tal Ltd.’s ("IRRI-Al-Tal") previously announced brokered private placement of units...
Apr 23, 2018 02:30 am ET
BriaCell Activates A Clinical Site in Florida for Phase IIa Study of its Lead Candidate in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Sylvester Comprehensive Cancer Center...
Apr 18, 2018 05:30 am ET
BriaCell Provides Highlights of Scientific and Clinical Findings at AACR
- Early data points to safety and early efficacy of Bria-IMT™ in Advanced Stage IV Breast cancer -
Apr 11, 2018 04:00 am ET
Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, is Featured in an Exclusive New Audio Interview with SmallCapVoice.com
AUSTIN, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (TSXV:BCT.V) (OTC:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President & CEO, Dr. Williams,...
Apr 10, 2018 04:30 am ET
BriaCell to Present Encouraging Clinical Data at AACR 2018
- Early Evidence of Safety and Impressive Anti-Tumor Activity of Bria-IMT™ -
Apr 03, 2018 04:30 am ET
BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal
BERKELEY, Calif. and VANCOUVER, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the acceptance of a manuscript...
Mar 27, 2018 04:30 am ET
Mar 14, 2018 08:21 am ET
BriaCell Appoints Top Social Media Marketing Analyst
BERKELEY, Calif. and VANCOUVER, British Columbia, March 14, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it has engaged Akari Health, a leading...
Mar 07, 2018 02:59 pm ET
Mar 01, 2018 03:30 am ET
BriaCell To Present at Precision Breast Cancer Conference
BERKELEY, Calif. and VANCOUVER, British Columbia, March 01, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that Dr. Bill Williams, BriaCell’s President & CEO,...
Feb 07, 2018 03:30 am ET
BriaCell to Attend 20th Annual BIO CEO & Investor Conference
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 07, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be attending BIO CEO &...
Feb 06, 2018 03:30 am ET
BriaCell Opens Fourth Clinical Site in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 06, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the opening of a new...
Feb 05, 2018 03:30 am ET
BriaCell Presenting at Upcoming Cancer Conference
Further Investigation on Mechanism of Action of its Lead Drug Candidate, Bria-IMT™, at AACR event
Jan 31, 2018 03:30 am ET
BriaCell Update:  Early Evidence of Efficacy and Safety of Bria-IMT™
BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, provides an update on its operations.
Jan 03, 2018 07:56 am ET
BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer
BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 03, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is providing a clinical update regarding its ongoing clinical...
Jan 02, 2018 03:30 am ET
BriaCell To Attend Biotech Showcase™ 2018
BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 02, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be attending Biotech Showcase™ 2018....
Dec 21, 2017 09:58 am ET
BriaCell Announces Closing of Warrant Incentive Program
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES
Dec 05, 2017 10:41 am ET
Dr. Bill Williams Guest Appearance at “CEO MONEY” Radio Show
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that Dr. Bill Williams,...
Nov 13, 2017 03:30 am ET
BriaCell Announces Advancement of its Small Molecule Program and Patent Allowance
BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today disclosed the allowance by the US...
Nov 06, 2017 03:30 am ET
BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax™
BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 06, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today released a clinical update on its...
Oct 03, 2017 01:54 pm ET
BriaCell Announces Repricing of Warrants
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES...
Aug 02, 2017 04:30 am ET
BriaCell Announces Additional Capital Support by the CEO
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that Dr. William Williams, BriaCell's...
Jul 31, 2017 04:30 am ET
BriaCell Appoints Top Oncologist and Opens Second Clinical Site for its Ongoing Clinical Trial in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce the opening of a new clinical site, Florida...
Jul 24, 2017 04:30 am ET
BriaCell Expands Targeted Pipeline via Acquisition of Sapientia Pharmaceuticals
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that it has entered into a definitive share...
Jul 19, 2017 04:30 am ET
BriaCell Provides Clinical Update on its Ongoing Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, provided a clinical update regarding its US-based open-label Phase I/IIa clinical trial evaluating the...
Jul 05, 2017 04:30 am ET
BriaCell Completes Manufacturing of New Batch of BriaVax(TM)
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, announced today that it has successfully manufactured a new batch of its BriaVax™ vaccine, and that this...
Jun 01, 2017 04:30 am ET
BriaCell Doses Second Patient in Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company announced today it has enrolled the second patient in a USA-based open-label Phase I/IIa clinical trial...
May 31, 2017 04:30 am ET
BriaCell Launches Its Scientific Advisory Board
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), announced today the establishment of its Scientific Advisory Board (SAB) engaging a number of highly-experienced leading experts in the field of...
May 08, 2017 04:30 am ET
BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax(TM) in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, today announced dosing of the first patient in BriaCell's Phase I/IIa clinical trial evaluating the...
Mar 24, 2017 02:22 pm ET
BriaCell Closes CEO Equity Investment
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the "Offering") of 5,612,083 units (the "Units")...
Mar 15, 2017 04:30 am ET
BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax(TM) in Patients with Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today announced that the U.S. Food and Drug Administration (FDA) has...
Mar 07, 2017 03:30 am ET
BriaCell Files New Patent Application for its Whole-Cell Breast Cancer Vaccine and Companion Diagnostic Platforms
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) today announced that it has filed an international patent application under the Patent Cooperation Treaty (PCT) to further expand its intellectual property...
Feb 27, 2017 03:30 am ET
BriaCell CEO Equity Investment Advances Company's Lead Cancer Product and Pipeline Expansion
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) announced today that its President and CEO, Dr. William Williams has entered into a non-brokered private placement (the "Offering") of 5,416,667 units of the...
Feb 06, 2017 03:30 am ET
BriaCell Moves Forward to Initiate Phase I/IIa Clinical Study for BriaVax(TM) in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company has submitted a Chemistry,...
Jan 05, 2017 06:08 am ET
BriaCell Included in the List of Key Players in Immuno-Oncology
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of novel immuno-oncology therapeutics, today announced that Jason Napodano, senior...
Dec 05, 2016 03:30 am ET
BriaCell to Present at a Breast Cancer Symposium, and Enters into a Research Agreement with Terasaki Foundation Laboratory
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company will present the latest development...
Nov 29, 2016 03:30 am ET
BriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax(TM)
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments, is pleased to announce that it has filed a patent...
Nov 10, 2016 09:37 am ET
BriaCell Provides Clinical Development Update on BriaVax(TM)
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments that can enhance the lives of cancer patients, today...
Oct 26, 2016 07:27 am ET
BriaCell Announces the Appointment of Biotechnology Veteran William Williams as New CEO and Director
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments that can enhance the lives of cancer patients, is...
Sep 27, 2016 04:30 am ET
BioNap Consulting's Jason Napodano Issues an Update on BriaCell Therapeutics Corp.
BioNap Consulting, Inc.'s Senior Equity Analyst, Jason Napodano, CFA, issued an update outlining the meaningful progress of BriaCell Therapeutics Corp. (TSX VENTURE: BCT) (OTCQB: BCTXF) or BriaCell towards initiation of Phase I/IIa clinical testing...
Sep 15, 2016 04:30 am ET
BriaCell Appoints New York-Based RK Equity Advisors and TrueNorth Lifesciences as Corporate Advisor
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has entered into an agreement (the "Agreement") with RK Equity Advisors LLC and TrueNorth Lifesciences LLC ("RK TrueNorth")...
Aug 19, 2016 12:01 pm ET
BriaCell Closes Oversubscribed Non-Brokered Private Placement
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT)(OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the "Offering") of units (the "Units") for aggregate gross proceeds to the Company in the amount of $1,700,000.
Aug 19, 2016 12:01 pm ET
BriaCell Closes Oversubscribed Non-Brokered Private Placement
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE:BCT)(OTCQB:BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the "Offering") of units (the "Units") for aggregate...
Aug 17, 2016 04:30 am ET
BriaCell Appoints the Lead Principal Investigator and First Clinical Site for Its Upcoming Phase I/IIa Clinical Trial in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that Dr. Jarrod P. Holmes, a Board Certified Oncologist and a leading expert in breast cancer vaccines at Annadel Medical Group and...
Aug 12, 2016 04:37 am ET
BriaCell Announces Non-Brokered Private Placement
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES BriaCell Therapeutics Corp. (OTCQB:BCTXF)(TSX VENTURE:BCT) ("BriaCell", the "Company", or "BCT") announced today that it intends to complete a...
May 18, 2016 04:30 am ET
BriaCell Appoints Contract Research Organization, Cancer Insight, to Manage Its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has signed a definitive agreement with Cancer Insight, LLC, a cancer-vaccine focused clinical research organization (CRO), to...
May 10, 2016 04:30 am ET
BriaCell Adds U.S. Biotech Veteran to Its Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT)(OTCQB: BCTXF) today announced a change to its board of directors.BriaCell is pleased to welcome the appointment of Mr. Martin Schmieg to its Board of Directors. Mr....
May 03, 2016 04:30 am ET
BriaCell Completes Previously Announced Investment With Leading U.S. Biotech Fund and Non-Brokered Private Placement
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that the Company has completed both its previously announced brokered and non-brokered private placements of units totaling gross...
Apr 22, 2016 11:06 am ET
BriaCell Announces Non-Brokered Private Placement
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES BriaCell Therapeutics Corp. (TSX VENTURE:BCT)(OTCQB:BCTXF) ("BriaCell", the "Company", or "BCT") announced today that it intends to complete a non-brokered private...
Apr 22, 2016 05:03 am ET
BriaCell Announces Proposed Investment by Leading US Biotech Fund
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRE SERVICES BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE:BCT)(OTCQB:BCTXF) announced today that it has entered into a subscription agreement with a...
Apr 12, 2016 04:30 am ET
BriaCell Files a Patent Application to Protect Additional Cancer Vaccines With Genetic Features Thought to Promote Strong Anti-Tumor Activity
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining certain features...
Apr 05, 2016 05:33 am ET
BriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to provide an update in regard to the planned timing of its Phase I/II clinical trial for up to 24 late-stage cancer patients. BriaCell has...
Mar 29, 2016 05:30 am ET
BriaCell Discovers Gene Signature of BriaVax(TM) Cancer Vaccine Consistent With Exceptional Efficacy in Clinical Trial
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to announce that it has discovered a gene signature potentially explaining why its BriaVax™ cancer vaccine was exceptionally efficacious in...
Mar 24, 2016 01:30 pm ET
BriaCell Announces Senior Management Change
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX VENTURE: BCT) (the "Company") announces that Dr. Joseph Wagner has resigned his positions as President and Chief Executive Officer of the Company, effective immediately, in order to pursue other opportunities. Dr. Wagner has also stepped down from the Board. Mr. Rahoul Sharan, Director of the Company, has been appointed Chief Executive Officer on an interim basis as the Board searches for a suitable long-term replacement. Mr. Sharan brings 25 years of corporate finance experience where he has led financings in excess of several